Loading
AB
Assembly Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by GILEAD SCIENCES, INC., was filed 03 Oct 2025.
Assembly Biosciences, Inc.: what insiders have been doing
Assembly Biosciences, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). From 22 October 2025 to 22 October 2026, the disclosure feed for Assembly Biosciences, Inc. logged 16 filings by 6 insiders.
No insider bought on the market over the period, while 2 insiders filed 5 sales totalling €13k. At €7,256, the sale published on 31 March 2026 by Bjorkquist Jeanette M is the largest of the period (0.0016% of market cap).
For context, the typical company on the same exchange (median of 3,171 companies) published 24 filings over the same period, against 16 filings here. The full history, which starts in 2016, counts 18 purchases against 74 sales. The 10-K for the year ended 31 December 2025 shows 72.3 m USD of revenue and -6.1 m USD of net income.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
173
Thresholds
n/a
Buy Volume
€21M
18 ops. · all time
Sell Volume
€2M
74 ops. · all time
Who traded when
BuySaleJeanette M. Bjorkquist4 sales
Nicole S. White4 sales
Alexander Schornstein3 buys
Gilead Sciences, Inc.2 buys
Jason A. Okazaki1 sale
John G. McHutchison1 sale
+1 other insider
Since the insiders bought
- +96.8%Entry US$17.15 · Close at T+365 US$33.75
- +131.0%Entry US$14.72 · Close at T+365 US$34.00
- +124.5%Entry US$16.83 · Close at T+365 US$37.79
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,718 of 26,246 companies
21.4
score / 100
Value22
Quality21
FCF yld-9.9%
Earn yld-1.5%
EV/EBITDA·
ROE-0.0%
Gross mgn·
Net mgn-8.5%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$20.34
Analyst consensus
5 analysts1.00/5
US$43.00Target US$52.00(+156%)US$62.00
Income statement
RevenueUS$72.3M
EBITDA-US$12M-17% margin
Net income-US$6.1M-0.1% margin
Valuation
PER (trailing)19.6x
PER (forward)-7.9x
P/Book1.3x
Beta1.16
Balance sheet & cash
Market capUS$414.1M
Total debtUS$2.6M
Free Cash Flow-US$41.2M
Debt / Equity1%
Profitability & ownership
ROE-0.0%
ROA-2.7%
% insiders27.7%
% institutions69.6%
Last declaration on 18 June 2026
Declarations173 total
29 shares@ US$23.254.7% of flowCommon StockSEC:0001193125-26-275804:0
50,750 shares0Common StockSEC:0001193125-26-259517:0
14,000 shares0Common StockSEC:0001193125-26-259562:0
3,500 shares0Common StockSEC:0001193125-26-259661:0
14,000 shares0Common StockSEC:0001193125-26-259924:0
14,000 shares0Common StockSEC:0001193125-26-259927:0
471,698 shares@ US$26.502.36% mcap35.6% of flowCommon StockSEC:0001123292-26-000751:0
94,250 shares0Common StockSEC:0001193125-26-134496:0
26,000 shares0Common StockSEC:0001193125-26-134554:0
26,000 shares0Common StockSEC:0001193125-26-134601:0
26,000 shares0Common StockSEC:0001193125-26-134645:0
6,500 shares0Common StockSEC:0001193125-26-134669:0
188 shares@ US$26.65020.0010% mcap17.8% of flowCommon StockSEC:0001193125-26-134645:1
9 shares@ US$27.490.0000% mcap0.9% of flowCommon StockSEC:0001193125-26-134645:2
312 shares@ US$26.65020.0016% mcap61.4% of flowCommon StockSEC:0001193125-26-134669:1
16 shares@ US$27.490.0001% mcap3.2% of flowCommon StockSEC:0001193125-26-134669:2
2,295,920 sharesCommon StockSEC:0001123292-25-000510:0
Canonical exit: 6 Nov 2025 (T+90)
300 shares0Common StockSEC:0000950170-25-087346:0
757 shares@ US$9.84815.5% of flowCommon StockSEC:0000950170-25-054331:0
180 shares@ US$9.848113.9% of flowCommon StockSEC:0000950170-25-048487:1
197 shares@ US$9.84817.3% of flowCommon StockSEC:0000950170-25-048485:0
355 shares@ US$9.84815.0% of flowCommon StockSEC:0000950170-25-048486:0
1,655 shares0Common StockSEC:0000950170-25-048487:0
3,202 shares@ US$15.6145100.0% of flowCommon StockSEC:0000950170-24-141616:0
Canonical exit: 30 Mar 2025 (T+90)
940,499 shares@ US$21.3764.4% of flowCommon StockSEC:0000904454-24-000669:0
Canonical exit: 19 Mar 2025 (T+90)
25 of 173 declarations
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc. (NASDAQ: ASMB) is a United States-based biotechnology company headquartered in South San Francisco, California. The company was incorporated in Delaware in October 2005, originally as South Island Biosciences, Inc., later operating as Ventrus Biosciences before adopting the Assembly Biosciences name in 2014 following a merger with Assembly Pharmaceuticals. For investors, this is best characterized as a clinical-stage biotech story: value creation depends primarily on research execution, clinical readouts, partnering activity, and regulatory progress rather than commercial product sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001426800/000119312526115992/asmb-20251231.htm?utm_source=openai))
Assembly Biosciences develops innovative therapeutics for serious viral diseases, with a pipeline concentrated on herpesviruses and hepatitis-related infections. Its 2024 Annual Report states that the company’s clinical-stage portfolio includes two helicase-primase inhibitors for recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a next-generation capsid assembly modulator for hepatitis B virus (HBV), and a novel oral broad-spectrum non-nucleoside polymerase inhibitor aimed at transplant-related herpesviruses. This mix gives ASMB a focused, specialist profile rather than a broad platform biotech model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1426800/000095017025057331/asmb_-_2024_annual_repor.pdf))
Read moreShow less
In competitive terms, the company targets areas of significant unmet medical need where differentiation can come from mechanism of action, durability, oral convenience, and tolerability. In recurrent genital herpes, Assembly is aiming to deliver long-acting oral antivirals that could improve adherence and clinical control compared with more traditional approaches. In HBV and HDV, it is pursuing next-generation antiviral mechanisms in disease areas where current treatment options remain limited and where improved viral suppression is still a major goal. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1426800/000095017025057331/asmb_-_2024_annual_repor.pdf))
Recent news has been material. In 2025, Assembly reported positive Phase 1b results for ABI-4334 in chronic hepatitis B, highlighting favorable safety and pharmacokinetics supportive of once-daily oral dosing. In December 2025, the company disclosed positive interim Phase 1b data for ABI-1179 and ABI-5366 in recurrent genital herpes, including strong reductions in viral shedding and lesion rates. Most importantly, Gilead Sciences exercised its option to exclusively license Assembly’s herpes simplex virus helicase-primase inhibitor programs, including ABI-1179 and ABI-5366, a meaningful external validation of the platform and an important strategic milestone. ([investor.assemblybio.com](https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-reports-positive-topline-results-phase-1b?utm_source=openai))
The company is listed on NASDAQ in the United States and remains highly dependent on pipeline milestones. Its geographic footprint is concentrated in California, and its investment case is driven by clinical data, business development, and the ability to convert scientific promise into partner-backed or eventually commercial value. For French-speaking investors, ASMB is a high-risk, high-upside specialist antiviral biotech with clear catalyst sensitivity.
